Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D Collaboration Leads to Next-Generation Cell Therapy Research
Aspect and Novo Nordisk announce a partnership, using Aspect’s bioprinting technology and Novo Nordisk’s expertise, to develop treatments for diabetes.
Cell therapy moves forward across the pipeline
Beta cell replacement therapies aim to overcome the obstacles to realize their potential, but several approaches are making them a…
Verapamil Slows Type 1 Diabetes Progression in Newly Diagnosed Children and Teens
The CLVer study found that newly diagnosed individuals on verapamil were making more insulin one year after diagnosis than those…
“I Really Love Type 1 Diabetes Research, and I’m Not Going Back”
A goal of David Alagpulinsa, Ph.D., is to contribute to a treatment that makes people with type 1 diabetes live…
Breakthrough T1D Timeline: Stem Cell Therapies
Stem cells have the potential to lead to treatments for type 1 diabetes, but it has taken Breakthrough T1D more…
Vertex Provides an Update on the VX-880 Clinical Trial
Vertex provides an update on their Phase 1/2 Clinical Trial for VX-880, including data from three participants and details around…
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal…
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now…
